Lamzede® (velmanase alfa-tycv intravenous infusion)

Lamzede is covered for non‑central nervous system manifestations of alpha‑mannosidosis in FDA‑approved adult and pediatric patients, while CNS manifestations are excluded. Coverage requires alpha‑mannosidase activity <10% in blood leukocytes, biallelic pathogenic MAN2B1 variants, documentation of non‑CNS disease, prescription or consultation by a geneticist/endocrinologist/metabolic or lysosomal disorder specialist, dosing at 1 mg/kg IV weekly, and approvals are limited to 12 months.

"Lamzede (velmanase alfa-tycv) is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients."

Sign up to see full coverage criteria, indications, and limitations.